{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:58:37Z","timestamp":1777557517269,"version":"3.51.4"},"reference-count":114,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.clml.2023.06.006","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T21:18:31Z","timestamp":1686863911000},"page":"705-713","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["SOHO State of the Art Updates and Next Questions | From Biology to Therapy: Progress in Hodgkin Lymphoma"],"prefix":"10.1016","volume":"23","author":[{"given":"Karan L.","family":"Chohan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1244-6758","authenticated-orcid":false,"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clml.2023.06.006_bib0001","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","article-title":"Molecular biology of Hodgkin lymphoma","volume":"35","author":"Weniger","year":"2021","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.clml.2023.06.006_bib0002","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clml.2023.06.006_bib0003","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood.2022017147","article-title":"Novel insights into Hodgkin lymphoma biology by single-cell analysis","volume":"141","author":"Aoki","year":"2023","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.clml.2023.06.006_bib0004","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2010.32.8401","article-title":"Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment","volume":"29","author":"Steidl","year":"2011","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clml.2023.06.006_bib0005","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2023.06.006_bib0006","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.06.006_bib0007","article-title":"CD58 Immunobiology at a glance","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.clml.2023.06.006_bib0008","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/gene.2016.30","article-title":"CD58 mutations are common in Hodgkin lymphoma cell lines and loss of CD58 expression in tumor cells occurs in Hodgkin lymphoma patients who relapse","volume":"17","author":"Abdul Razak","year":"2016","journal-title":"Genes Immun"},{"issue":"10","key":"10.1016\/j.clml.2023.06.006_bib0009","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/gcc.22276","article-title":"Alterations of the CD58 gene in classical Hodgkin lymphoma","volume":"54","author":"Schneider","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"issue":"17","key":"10.1016\/j.clml.2023.06.006_bib0010","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2023.06.006_bib0011","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41408-019-0185-9","article-title":"Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma","volume":"9","author":"Jalali","year":"2019","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.clml.2023.06.006_bib0012","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00262-018-2282-1","article-title":"A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression","volume":"68","author":"Mahoney","year":"2019","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"10.1016\/j.clml.2023.06.006_bib0013","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin's lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2023.06.006_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204870","article-title":"Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma","volume":"13","author":"Hollander","year":"2018","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.clml.2023.06.006_bib0015","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1158\/0008-5472.CAN-06-0261","article-title":"Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege","volume":"66","author":"Ishida","year":"2006","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.clml.2023.06.006_bib0016","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1182\/blood-2013-06-508044","article-title":"Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells","volume":"122","author":"Greaves","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2023.06.006_bib0017","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood-2018-04-843714","article-title":"Mass cytometry of Hodgkin lymphoma reveals a CD4(+) regulatory T-cell-rich and exhausted T-effector microenvironment","volume":"132","author":"Cader","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2023.06.006_bib0018","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/s41591-020-1006-1","article-title":"A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma","volume":"26","author":"Cader","year":"2020","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.clml.2023.06.006_bib0019","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1080\/10428194.2020.1839651","article-title":"LAG-3 is expressed on a majority of tumor infiltrating lymphocytes in pediatric Hodgkin lymphoma","volume":"62","author":"Moerdler","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.clml.2023.06.006_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001014","article-title":"LAG-3: from molecular functions to clinical applications","volume":"8","author":"Maruhashi","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.clml.2023.06.006_bib0021","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/bloodadvances.2019001390","article-title":"LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma","volume":"4","author":"Keane","year":"2020","journal-title":"Blood Adv"},{"issue":"22","key":"10.1016\/j.clml.2023.06.006_bib0022","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1182\/blood.V128.22.2952.2952","article-title":"Strong expression of the immune checkpoint regulators LAG3 and Tim3 in Hodgkin Lymphoma","volume":"128","author":"el Halabi","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.06.006_bib0023","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and Anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front Oncol"},{"issue":"23","key":"10.1016\/j.clml.2023.06.006_bib0024","first-page":"2059","article-title":"The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2023.06.006_bib0025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1200\/JCO.2013.53.1194","article-title":"Treatment of Hodgkin lymphoma: a 50-year perspective","volume":"32","author":"Canellos","year":"2014","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clml.2023.06.006_bib0026","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.clml.2023.06.006_bib0027","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of Pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.clml.2023.06.006_bib0028","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2023.06.006_bib0029","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of Nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin study group NIVAHL Trial","volume":"6","author":"Brockelmann","year":"2020","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.clml.2023.06.006_bib0030","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen","year":"2021","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.clml.2023.06.006_bib0031","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with Pembrolizumab in patients with classical Hodgkin lymphoma after Brentuximab Vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2023.06.006_bib0032","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2023.06.006_bib0033","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus Brentuximab Vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clml.2023.06.006_bib0034","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41375-020-0939-1","article-title":"A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed\/refractory lymphoid malignancies","volume":"35","author":"Armand","year":"2021","journal-title":"Leukemia"},{"issue":"28","key":"10.1016\/j.clml.2023.06.006_bib0035","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II Trial of Pembrolizumab plus gemcitabine, Vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2023.06.006_bib0036","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2023.06.006_bib0037","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.clml.2023.06.006_bib0038","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","article-title":"Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1\/2 trial","volume":"7","author":"Diefenbach","year":"2020","journal-title":"Lancet Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.06.006_bib0039","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood-2022-163787","article-title":"Pembrolizumab and chemotherapy in newly-diagnosed, early unfavorable or advanced stage classic Hodgkin lymphoma: the phase 2 Keynote-C11 study","volume":"140","author":"Advani","year":"2022","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.06.006_bib0040","first-page":"23","article-title":"SWOG S1826: A Phase III, randomized study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in patients with newly diagnosed advanced stage classical Hodgkin lymphoma","volume":"136","author":"Herrera","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.06.006_bib0041","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(18)30192-3","article-title":"Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial","volume":"6","author":"Shi","year":"2019","journal-title":"Lancet Haematol"},{"issue":"15_suppl","key":"10.1016\/j.clml.2023.06.006_bib0042","doi-asserted-by":"crossref","first-page":"8034","DOI":"10.1200\/JCO.2020.38.15_suppl.8034","article-title":"Sintilimab for relapsed\/refractory classical Hodgkin's lymphoma: Long-term follow-up on the multicenter, single-arm phase II ORIENT-1 study","volume":"38","author":"Su","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2023.06.006_bib0043","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41375-019-0545-2","article-title":"Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study","volume":"34","author":"Song","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2023.06.006_bib0044","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1158\/1078-0432.CCR-21-2023","article-title":"Tislelizumab for Relapsed\/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis","volume":"28","author":"Song","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2023.06.006_bib0045","article-title":"Penpulimab for relapsed or refractory classical Hodgkin lymphoma: a multicenter, single-arm, pivotal phase I\/II Trial (AK105-201)","volume":"12","author":"Song","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2023.06.006_bib0046","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejca.2021.07.021","article-title":"Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: a multicenter, single-arm, phase II study","volume":"164","author":"Lin","year":"2022","journal-title":"Eur J Cancer"},{"issue":"24","key":"10.1016\/j.clml.2023.06.006_bib0047","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1158\/1078-0432.CCR-19-1680","article-title":"A single-arm, multicenter, phase II study of camrelizumab in relapsed or refractory classical hodgkin lymphoma","volume":"25","author":"Song","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.clml.2023.06.006_bib0048","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/ijc.33852","article-title":"Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: Extended follow-up of the multicenter, single-arm, Phase 2 study","volume":"150","author":"Wu","year":"2022","journal-title":"Int J Cancer"},{"issue":"17","key":"10.1016\/j.clml.2023.06.006_bib0049","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1200\/JCO.18.02151","article-title":"Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed\/refractory classical hodgkin lymphoma","volume":"37","author":"Nie","year":"2019","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.06.006_bib0050","doi-asserted-by":"crossref","first-page":"6579","DOI":"10.1182\/blood-2022-166829","article-title":"Phase II clinical trial of camrelizumab combined with AVD (Epirubicin, Vincristine and Dacarbazine) in the first-line treatment for patients with advanced classical Hodgkin's lymphoma","volume":"140","author":"Zhao","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.06.006_bib0051","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-020-00886-2","article-title":"Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.clml.2023.06.006_bib0052","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(17)30239-5","article-title":"Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial","volume":"18","author":"Heery","year":"2017","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.clml.2023.06.006_bib0053","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1182\/bloodadvances.2021004511","article-title":"Avelumab in relapsed\/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial","volume":"5","author":"Herrera","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.clml.2023.06.006_bib0054","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/01.HS9.0000847212.00073.29","article-title":"P1086: Favezelimab (anti\u2013lag-3) and Pembrolizumab co-blockade in anti\u2013pd-1\u2013naive patients with relapsed or refractory classical Hodgkin lymphoma: an open-label phase 1\/2 study","author":"Gregory","year":"2022","journal-title":"HemaSphere"},{"issue":"16_suppl","key":"10.1016\/j.clml.2023.06.006_bib0055","doi-asserted-by":"crossref","first-page":"7545","DOI":"10.1200\/JCO.2022.40.16_suppl.7545","article-title":"Favezelimab (anti\u2013LAG-3) plus pembrolizumab in patients with relapsed or refractory (R\/R) classical Hodgkin lymphoma (cHL) after anti\u2013PD-1 treatment: An open-label phase 1\/2 study","volume":"40","author":"Timmerman","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.06.006_bib0056","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood-2022-166670","article-title":"Updated results from an open-label phase 1\/2 Study of Favezelimab (anti-LAG-3) plus pembrolizumab in relapsed or refractory classical Hodgkin lymphoma after Anti-PD-1 treatment","volume":"140","author":"Timmerman","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2023.06.006_bib0057","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.4049\/jimmunol.172.4.2186","article-title":"Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in vitro","volume":"172","author":"Matsumoto","year":"2004","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.clml.2023.06.006_bib0058","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V85.1.1.bloodjournal8511","article-title":"CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy","volume":"85","author":"Falini","year":"1995","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2023.06.006_bib0059","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.clml.2023.06.006_bib0060","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2023.06.006_bib0061","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clml.2023.06.006_bib0062","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2023.06.006_bib0063","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1182\/bloodadvances.2020001871","article-title":"ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma","volume":"4","author":"Park","year":"2020","journal-title":"Blood Advances"},{"issue":"3","key":"10.1016\/j.clml.2023.06.006_bib0064","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clml.2023.06.006_bib0065","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/bjh.15539","article-title":"Prospective study of brentuximab vedotin in relapsed\/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy","volume":"183","author":"Walewski","year":"2018","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.clml.2023.06.006_bib0066","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","article-title":"Results of a multicenter phase II trial of Brentuximab Vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodgkin lymphoma","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2023.06.006_bib0067","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2023.06.006_bib0068","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/annonc\/mdz009","article-title":"Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)","volume":"30","author":"Garcia-Sanz","year":"2019","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.clml.2023.06.006_bib0069","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41409-019-0454-z","article-title":"Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma","volume":"54","author":"Abuelgasim","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl_1","key":"10.1016\/j.clml.2023.06.006_bib0070","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1182\/blood-2019-123925","article-title":"Brentuximab Vedotin in first refractory\/relapsed classical Hodgkin lymphoma patients treated by chemotherapy (ICE) before autologous transplantation. final analysis of phase II study","volume":"134","author":"Stamatoullas","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2023.06.006_bib0071","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1470-2045(18)30426-1","article-title":"Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial","volume":"19","author":"Cole","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9980","key":"10.1016\/j.clml.2023.06.006_bib0072","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"The Lancet"},{"issue":"12","key":"10.1016\/j.clml.2023.06.006_bib0073","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of Brentuximab Vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2023.06.006_bib0074","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1200\/JCO.21.01281","article-title":"Brentuximab Vedotin Plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial","volume":"41","author":"Fornecker","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2023.06.006_bib0075","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1080\/10428194.2022.2100369","article-title":"Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin","volume":"63","author":"Guan","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.06.006_bib0076","doi-asserted-by":"crossref","first-page":"9399","DOI":"10.1182\/blood-2022-156576","article-title":"Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin lymphoma: interim efficacy and safety results from the single-arm phase 2 study (SGN35-027 Part C)","volume":"140","author":"Lee","year":"2022","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.06.006_bib0077","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2021-147891","article-title":"Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for advanced stage classic Hodgkin lymphoma: preliminary safety results from the single-arm phase 2 study (SGN35-027 Part B)","volume":"138","author":"Lee","year":"2021","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.06.006_bib0078","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1182\/blood-2022-159258","article-title":"Frontline PET-directed therapy with Brentuximab Vedotin plus AVD Followed By Nivolumab consolidation in patients with limited stage Hodgkin lymphoma","volume":"140","author":"Park","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2023.06.006_bib0079","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3026(21)00103-4","article-title":"Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study","volume":"8","author":"Hamadani","year":"2021","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.clml.2023.06.006_bib0080","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/01.HS9.0000843696.37630.1c","article-title":"S201: Camidanlumab Tesirine: updated efficacy and safety in an open-label, multicenter, phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R\/R CHL)","author":"Carlo-Stella","year":"2022","journal-title":"HemaSphere"},{"issue":"8","key":"10.1016\/j.clml.2023.06.006_bib0081","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10301","key":"10.1016\/j.clml.2023.06.006_bib0082","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.clml.2023.06.006_bib0083","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2023.06.006_bib0084","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1080\/10428194.2022.2095623","article-title":"AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial","volume":"63","author":"Sasse","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"10.1016\/j.clml.2023.06.006_bib0085","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood.2019004701","article-title":"A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"136","author":"Bartlett","year":"2020","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.06.006_bib0086","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1182\/blood-2022-156125","article-title":"Innate cell engager AFM13 combined with preactivated and expanded cord blood-derived NK cells for patients with double refractory CD30+ Lymphoma","volume":"140","author":"Nieto","year":"2022","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.06.006_bib0087","doi-asserted-by":"crossref","first-page":"11753","DOI":"10.1182\/blood-2022-159524","article-title":"A phase 1, first-in-human, dose-escalation study of MGD024, a CD123 x CD3 Bispecific Dart\u00ae Molecule, in patients with relapsed or refractory CD123-Positive (+) hematologic malignancies","volume":"140","author":"Winer","year":"2022","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1016\/j.clml.2023.06.006_bib0088","first-page":"A481","article-title":"461\u2005Generation of AZD7789, a novel PD-1 and TIM-3 targeting bispecific antibody, which binds to a differentiated epitope of TIM-3","volume":"10","author":"Clancy-Thompson","year":"2022","journal-title":"J Immuno Ther Cancer"},{"issue":"10","key":"10.1016\/j.clml.2023.06.006_bib0089","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.clml.2023.06.006_bib0090","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.clml.2023.06.006_bib0091","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clml.2023.06.006_bib0092","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2023.06.006_bib0093","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10254","key":"10.1016\/j.clml.2023.06.006_bib0094","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.clml.2023.06.006_bib0095","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.20040890","article-title":"Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease","volume":"200","author":"Bollard","year":"2004","journal-title":"J Exp Med"},{"issue":"8","key":"10.1016\/j.clml.2023.06.006_bib0096","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2023.06.006_bib0097","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J Clin Invest"},{"issue":"32","key":"10.1016\/j.clml.2023.06.006_bib0098","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.06.006_bib0099","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2022-167504","article-title":"Phase 1 clinical trial of memory-enriched academic HSP-CAR30 for the treatment of relapsed\/refractory Hodgkin lymphoma and CD30+ T-Cell lymphoma: clinical and biological studies","volume":"140","author":"Caballero Gonzalez","year":"2022","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.06.006_bib0100","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood-2022-160244","article-title":"CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) provide a safe and effective off-the-shelf therapy for patients with CD30-positive lymphoma","volume":"140","author":"Quach","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2023.06.006_bib0101","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1158\/2159-8290.CD-16-0850","article-title":"Overcoming the immunosuppressive tumor microenvironment of Hodgkin lymphoma using chimeric antigen receptor T cells","volume":"7","author":"Ruella","year":"2017","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.clml.2023.06.006_bib0102","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19020340","article-title":"Incorporation of immune checkpoint blockade into chimeric antigen receptor T Cells (CAR-Ts): combination or built-In CAR-T","volume":"19","author":"Yoon","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clml.2023.06.006_bib0103","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3389\/fphar.2020.00557","article-title":"Immune checkpoint inhibitor-related cytokine release syndrome: analysis of WHO Global Pharmacovigilance Database","volume":"11","author":"Ceschi","year":"2020","journal-title":"Front Pharmacol"},{"issue":"22","key":"10.1016\/j.clml.2023.06.006_bib0104","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2017-11-814913","article-title":"Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma","volume":"131","author":"Tiacci","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2023.06.006_bib0105","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2023.06.006_bib0106","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clml.2023.06.006_bib0107","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/ejh.13859","article-title":"JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)","volume":"109","author":"Gillessen","year":"2022","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2023.06.006_bib0108","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1186\/s12885-019-6303-z","article-title":"Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma","volume":"19","author":"Kim","year":"2019","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.clml.2023.06.006_bib0109","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3324\/haematol.2017.180554","article-title":"A phase II study of the oral JAK1\/JAK2 inhibitor ruxolitinib in advanced relapsed\/refractory Hodgkin lymphoma","volume":"103","author":"Van Den Neste","year":"2018","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.clml.2023.06.006_bib0110","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clml.2014.01.007","article-title":"Status of PI3K\/Akt\/mTOR pathway inhibitors in lymphoma","volume":"14","author":"Westin","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.clml.2023.06.006_bib0111","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/annonc\/mdx028","article-title":"Phase II study of idelalisib, a selective inhibitor of PI3Kdelta, for relapsed\/refractory classical Hodgkin lymphoma","volume":"28","author":"Gopal","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.clml.2023.06.006_bib0112","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2004-11-4513","article-title":"A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein beta and NF-kappaB activity in Hodgkin and anaplastic large cell lymphomas","volume":"106","author":"Jundt","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.06.006_bib0113","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40164-018-0103-z","article-title":"Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma","volume":"7","author":"Johnston","year":"2018","journal-title":"Exp Hematol Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.06.006_bib0114","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2020-140507","article-title":"Everolimus plus Itacitinib in relapsed\/refractory classical Hodgkin lymphoma: results of a phase I\/II Investigator Initiated Trial (EVITA Study)","volume":"136","author":"Svoboda","year":"2020","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502300188X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502300188X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:43:04Z","timestamp":1761871384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502300188X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":114,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S215226502300188X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.06.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | From Biology to Therapy: Progress in Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}